Huntingtin aggregation and toxicity in Huntington's disease

@article{Bates2003HuntingtinAA,
  title={Huntingtin aggregation and toxicity in Huntington's disease},
  author={G. Bates},
  journal={The Lancet},
  year={2003},
  volume={361},
  pages={1642-1644}
}
  • G. Bates
  • Published 2003
  • Medicine
  • The Lancet
CONTEXT Huntington's disease is a late onset neurodegenerative disorder for which the mutation is a CAG/polyglutamine (polyQ) repeat expansion in the gene encoding the huntingtin protein. The disease is one of nine inherited neurodegenerative disorders that are caused by this type of mutation, and which include dentatorubral pallidoluysian atrophy, spinal and bulbar muscular atrophy, and the spinocerebellar ataxias 1, 2, 3, 6, 7, and 17. The mutant proteins are unrelated except for the polyQ… Expand
The P42 peptide and Peptide-based therapies for Huntington’s disease
Huntington's disease: From molecular basis to therapeutic advances.
Essential fatty acids in Huntington's disease.
The role of the proteasome in Huntington’s disease
Huntington's disease, calcium, and mitochondria.
Huntingtin and the molecular pathogenesis of Huntington's disease
Polyglutamine (PolyQ) Diseases: Genetics to Treatments
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology.
Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology
Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation
Huntington's disease.
...
1
2
3
...